Use of fullerene structure in preparation of medicaments for treating parkinson's disease

Abstract

An application of a fullerene structure in the preparation of medications for treating Parkinson's disease. The fullerene structure comprises at least one of the following active ingredient groups: a fullerene, a metallofullerene, and a composition of the fullerene and the metallofullerene; an oil-soluble fullerene, an oil-soluble metallofullerene, and a composition of the oil-soluble fullerene and the oil-soluble metallofullerene; a water-soluble fullerene, a water-soluble metallofullerene, and a composition of the water-soluble fullerene and the water-soluble metal-lofullerene; the medicinal esters of the nine elements, or the medicinal salts of the nine elements.

1 . A method of treating Parkinson's disease, comprising the step of: administering an effective dose of a fullerene structure to a subject in need of treatment for Parkinson's disease, wherein the fullerene structure comprises oil-soluble C 60  or oil-soluble C 70 . 
     
     
         2 . The method according to  claim 1 , wherein the oil-soluble C 60  is obtained through oil-soluble modification of C 60 , and the oil-soluble C 70  is obtained through oil-soluble modification of C 70 . 
     
     
         3 . The method according to  claim 2 , wherein the oil-soluble modification of C 60  disperses the C 60  in the oil solution to obtain an oil-soluble modified liquid. 
     
     
         4 . The method according to  claim 2 , the oil-soluble modification of C 60  comprises the step of coating the C 60  with a first oil solution, and the oil-soluble modification of C 70  comprises the step of coating the C 70  with a second oil solution. 
     
     
         5 . The method according to  claim 4 , wherein the first oil solution or the second oil solution is a single ingredient oil or a mixture of different oils, and the oil is one or more of vegetable oil or animal fat. 
     
     
         6 . The method according to  claim 5 , wherein the oil is selected from olive oil, linseed oil, sunflower oil, corn germ oil, soybean oil, or squalane. 
     
     
         7 . The method according to  claim 6 ; wherein the dispersing comprises:
 ball milling or ultrasonication of the mixture of the C 60  and the oil solution, followed by centrifugation to remove the precipitate, and filtration of the resulting supernatant.   
     
     
         8 . The method according to  claim 6 , wherein a concentration of the C 60  in the oil-soluble C 60  is from 0.01 to 100 mg/mL. 
     
     
         9 . The method according to  claim 6 , wherein a concentration of the C60 in the oil-soluble C60 is from 0.4 to 0.8 mg/mL. 
     
     
         10 . The method according to  claim 2 , wherein the oil-soluble modification of C 70  disperses the C 70  in the oil solution to obtain an oil-soluble modified liquid. 
     
     
         11 . The method according to  claim 10 , wherein the dispersing comprises:
 ball milling or ultrasonication of the mixture of the C 70  and the oil solution, followed by centrifugation to remove the precipitate, and filtration of the resulting supernatant.   
     
     
         12 . The method according to  claim 10 , wherein a concentration of the C 70  in the oil-soluble C 70  is from 0.01 to 100 mg/mL. 
     
     
         13 . The method according to  claim 10 , wherein a concentration of the C 70  in the oil-soluble C 70  is from 0.4 to 0.8 mg/mL 
     
     
         14 . The method according to  claim 1 , wherein the Parkinson's disease includes physical disabilities and dyskinesia caused by Parkinson's disease, including limbs tremor, rigid limbs, hypokinesia, bradykinesia, or discordant movement. 
     
     
         15 . The method according to  claim 1 , wherein the fullerene structure is applied at a dose of from 0.01 mg/kg/d to 1000 mg/kg/d. 
     
     
         16 . The method according to  claim 1 , wherein the fullerene structure is applied at a dose of from 0.1 to 10 mg/kg/d, or 4 mg/kg/d. 
     
     
         17 . The method according to  claim 1 , wherein the C 60  or the C 70  of fullerene structure is applied at a dose of from 0.5655 mg/kg/d to 1.131 mg/kg/d. 
     
     
         18 . The method according to  claim 17 , wherein the fullerene structure is administered orally, by injection or intraperitoneally. 
     
     
         19 . The method according to  claim 1 , wherein the subject is a human, a mouse, a guinea pig, a rat, a dog, a rabbit, or a monkey. 
     
     
         20 . The method according to  claim 1 , wherein the fullerene structure comprises C 60  coated with olive oil.